Common AIDS-associated opportunistic infections

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 8, Issue 5, 2008, Pages 539-543

  Ong, E L C ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

CD4 count; Cryptococcosis; Pneumocystis; Toxoplasmosis

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ATOVAQUONE; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; FLUCYTOSINE; FOLINIC ACID; PENTAMIDINE; PRIMAQUINE; PYRIMETHAMINE; PYRIMETHAMINE SULFADIAZINE; PYRROLE DERIVATIVE; SULFADIAZINE; TRIMETREXATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; IMMUNOCOMPETENCE; LIVER TOXICITY; LUNG INFILTRATE; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; SPUTUM EXAMINATION; THORAX RADIOGRAPHY; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 55049139601     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.8-5-539     Document Type: Article

References (19)

1. Dybul M, Fauci AS, Bartlett JG et al. Panel on Clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137(5 Pt 2):381-433.
2. Masur H, Ognibene FP, Yarchoan R et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989;111:223-31.
3. Murray JF, Felton CP, Garay SM et al. Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute workshop. N Engl J Med 1984;310:1682-8.
4. Kaplan JE, Hanson D, Dworkin MS et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 1):S5-14.
5. Wachter RM, Luce JM, Turner J, Volberding P, Hopewell PC. Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. Am Rev Respir Dis 1986; 134:891-6.
6. Ong EL, Hanley SP, Mandal BK. Bronchial responsiveness in AIDS patients with Pneumocystis carinii pneumonia. AIDS 1992;6:1331-3.
7. Rankin JA, Collman R, Daniele RP. Acquired immune deficiency syndrome and the lung. Chest 1988;94:155-64.
8. Homer KS, Wiley EL, Smith AL et al. Monoclonal antibody to Pneumocystis carinii. Comparison with silver stain in bronchial lavage specimens. Am J Clin Pathol 1992;97:619-24.
9. Wharton JM, Coleman DL, Wofsy CB et al. Trimethoprimsulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986; 105:37-44.
10. Bozzette SA, Sattler FR, Chin J et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1990;323:1451-7.
11. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Review. Clin Infect Dis 1992;15:211-22.
12. Schnapp LM, Geaghan SM, Campagna A et al. Toxoplasma gondii pneumonitis in patients infected with the human immunodeficiency virus. Arch Intern Med 1992;152:1073-7.
13. Dannemann B, McCutchan JA, Israelski D et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 1992; 116:33-43.
14. Torre D, Casari S, Speranza F et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother 1998;42:1346-9.
15. Murphy EL, Collier AC, Kalish LA et al. Viral Activation Transfusion Study Investigators. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.
16. Hajjeh RA, Conn LA, Stephens DS et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis 1999;179: 449-54.
17. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:710-8.
18. van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21.
19. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK; CDC; National Institutes of Health; Infectious Diseases Society of America. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004;53(RR-15):1-112.